Want to see OVID full AI Analyst Report?
Top Page
Ovid Therapeutics
(NASDAQ:OVID)
Select Model
Select Model
Rating:53Neutral
Price Target:
$2.50
▲(7.30% Upside)
Action:Reiterated
Date:07/09/26
The score is held back primarily by weak financial performance—ongoing losses and negative free cash flow—despite low leverage. Technicals add support given the stock’s position above key moving averages and positive momentum. Corporate events modestly improve the outlook via added capital, while valuation remains limited by negative earnings and no dividend data.
Positive Factors
Low leverage / strong balance sheet
Ovid’s trailing‑twelve‑month debt‑to‑equity of ~0.01 indicates very low financial leverage and limited near‑term solvency risk. This structural strength provides flexibility to fund clinical programs and absorb operating losses without immediate refinancing, supporting program continuity over months.
Negative Factors
Persistent negative cash flow
Ovid has sustained negative operating and free cash flow across multiple years, reflecting an ongoing cash burn. Even with some TTM improvement, internal cash generation is insufficient to fully fund development programs, increasing reliance on external capital and constraining strategic flexibility over months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Ovid’s trailing‑twelve‑month debt‑to‑equity of ~0.01 indicates very low financial leverage and limited near‑term solvency risk. This structural strength provides flexibility to fund clinical programs and absorb operating losses without immediate refinancing, supporting program continuity over months.
Read all positive factors
Ovid Therapeutics (OVID) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$489.00M
Dividend YieldN/A
Average Volume (3M)3.08M
Price to Earnings (P/E)―
Beta (1Y)2.24
Revenue Growth1199.64%
EPS Growth30.81%
CountryUS
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.36
Shares Outstanding186,640,100
10 Day Avg. Volume1,602,590
30 Day Avg. Volume3,084,969
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)0.92
Price to Sales (P/S)16.57
P/FCF Ratio-3.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.25Price Target Upside168.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$134.38K
Ovid Therapeutics Business Overview & Revenue Model
Company Description
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeuti...
How the Company Makes Money
Ovid Therapeutics primarily makes money through collaboration-related revenue rather than product sales (as public information about sustained, material commercial product revenue is not available). Its revenue model typically includes: (1) Upfron...
Ovid Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
66
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.58M | 7.25M | 566.00K | 392.00K | 1.50M | 208.38M |
| Gross Profit | 815.00K | 6.95M | 566.00K | 392.00K | 1.50M | 208.38M |
| EBITDA | -35.11M | -17.11M | -57.77M | -57.01M | -54.17M | 124.45M |
| Net Income | -34.49M | -17.41M | -26.43M | -52.34M | -54.17M | 122.83M |
Balance Sheet | ||||||
| Total Assets | 231.97M | 150.93M | 92.17M | 144.03M | 155.27M | 194.54M |
| Cash, Cash Equivalents and Short-Term Investments | 117.22M | 69.64M | 53.08M | 105.83M | 129.00M | 187.80M |
| Total Debt | 1.48M | 13.42M | 14.76M | 16.00M | 16.54M | 0.00 |
| Total Liabilities | 22.08M | 20.27M | 23.94M | 56.23M | 22.99M | 14.80M |
| Stockholders Equity | 209.89M | 130.66M | 68.23M | 87.80M | 132.27M | 179.75M |
Cash Flow | ||||||
| Free Cash Flow | -54.77M | -38.33M | -56.03M | -45.92M | -56.65M | 118.42M |
| Operating Cash Flow | -54.77M | -38.33M | -55.96M | -45.78M | -55.23M | 118.61M |
| Investing Cash Flow | -147.80M | -49.85M | 54.59M | -2.58M | -87.88M | -1.82M |
| Financing Cash Flow | 185.78M | 75.21M | 622.00K | 30.54M | 180.66K | 904.08K |
Ovid Therapeutics Technical Analysis
Positive
2.33
Price Trends
2.46
Positive
2.54
Positive
2.07
Positive
Market Momentum
0.04
Negative
57.39
Neutral
82.99
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OVID, the sentiment is Positive. The current price of 2.33 is below the 20-day moving average (MA) of 2.44, below the 50-day MA of 2.46, and above the 200-day MA of 2.07, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 57.39 is Neutral, neither overbought nor oversold. The STOCH value of 82.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OVID.
Ovid Therapeutics Risk Analysis
Ovid Therapeutics disclosed 57 risk factors in its most recent earnings report. Ovid Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ovid Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $334.89M | -5.07 | -42.80% | ― | ― | 59.89% | |
54 Neutral | $307.47M | -1.69 | -87.95% | ― | -100.00% | 14.08% | |
53 Neutral | $489.00M | -7.78 | -22.51% | ― | 1199.64% | 30.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $312.82M | -2.93 | 1147.63% | ― | -36.09% | 24.84% | |
44 Neutral | $92.78M | -2.58 | -171.19% | ― | ― | 83.55% | |
42 Neutral | $284.32M | -0.58 | 187.62% | ― | -8.79% | -195.46% |
* Healthcare Sector Average
OVID
Ovid Therapeutics
2.80
1.96
233.33%
IRD
Opus Genetics
3.72
2.54
215.25%
ZNTL
Zentalis Pharmaceuticals
4.15
2.67
180.41%
IKT
Inhibikase Therapeutics
2.41
0.70
40.94%
SRZN
Surrozen
23.73
12.88
118.71%
BMEA
Biomea Fusion
1.28
-0.41
-24.26%
Ovid Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Ovid Therapeutics appoints Charles Carter as new CFO
Positive
Jul 8, 2026
On July 5, 2026, Ovid Therapeutics Inc. agreed with Chief Business and Financial Officer Jeffrey Rona on his transition from all officer roles, effective July 6, 2026, with the company stressing his departure was not due to any disagreement over f...
Executive/Board ChangesShareholder Meetings
Ovid Therapeutics Shareholders Back Board and Governance Proposals
Positive
Jun 11, 2026
Ovid Therapeutics Inc. held its annual meeting of stockholders on June 10, 2026, with 75.7% of eligible shares represented, and shareholders elected Jeremy M. Levin to a three-year term on the board of directors. Investors also approved, on an adv...
Business Operations and StrategyExecutive/Board Changes
Ovid Therapeutics Expands Board, Appoints New Scientific Director
Positive
Jun 3, 2026
On May 29, 2026, Ovid Therapeutics’ board approved an expansion of its board of directors, effective June 15, 2026, and appointed physician-scientist Anna Greka as a Class III director with a term running until the 2029 annual shareholders&#...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.